References

  1. Parker SL, Tong T, Colden S,et al.Cancer Statistics, 1996.CA: A Cancer Journal for Clinicians.1996;46:5-27.

  2. Gibas Z, Gibas L.,Cytogenetics of bladder cancer.Cancer Genet Cytogenet.1997;95:108-115.

  3. Raghavan D, Shipley WU, Garnick MS,et al.Biology and management of bladder cancer.N Engl J Med.1990;22:1129-1138.

  4. Fair WR, Fuks ZY, Scher HI. Cancer:,Principles Practice of Oncology, 4th ed. (ed. DeVita VT, Hellman S, Rosenberg SA). J.B. Lippincott Co., Philadelphia, PA.1993:1052-1072.

  5. Mao L, Schoenberg MP, Scicchitano M,et al.Molecular detection of primary cancer by microsatellite analysis.Science.1996;271:659-662.

  6. Sarosdy MF, deVere White RW, Soloway MS,et al.Results of a multicenter trial using BTA Test to monitor for and diagnose recurrent bladder cancer.J Urol.1995;154:379.

  7. Waldman FM, Carroll PR, Kerschmann R,et al.Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer.Cancer Res.1991;51:3807-3813.

  8. Smeets AWGB, Schapers R, Hompan AHN,et al.Concordance between karyotyping and in situ hybridization procedures in the detection of monosomy 9 bladder cancer.Cancer Genet Cytogenet.1993;71:97-99.

  9. Sauter G, Moch H, Wagner U,et al.Y chromosome loss detected by FISH in bladder cancer.Cancer Genet Cytogenet.1995;82:163-169.

  10. Matsuyama H, Bergerheim USR, Nilsson I,et al.Nonrandom numerical aberrations of chromosomes 7, 9, and 10 in DNA-diploid bladder cancer.Cancer Genet Cytogenet.1994;77:118-124.

  11. Hopman AHN, Moesker O, Smeets AWGB,et al.Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization.Cancer Res.1991;51:644-651.

  12. Cajulis RS, Haines GK, Frias-Hidvegi D,et al.Cytology, flow cytometry, image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study.Diagnostic Cytopathology.1997;13:214-224.

  13. Meloni AM, Peier AM, Haddad FS,et al.A new approach in the diagnosis and follow-up bladder cancer: FISH analysis of urine, bladder washings, and tumors.Cancer Genet Cytogenet.1993;71:105-118.

  14. Meloni AM, Peier AM, Kingsley KL,et al.FISH studies of urinary cells of patients with bladder cancer.Urol Oncol.1995;1:234-239.

  15. Wheeless LL, Reeder JE, Han R,et al.Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei.Cytometry.1994;17:319-326.

  16. U.S. Centers for Disease Control,Morbidity and Mortality Weekly Review.1987;36(suppl. 2S):2S-18S.

  17. Sokolova IA, Halling KC, Jenkins RB,et al.The development of a multitarget multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.J Mol Diagn.2000;2(3):116-123.

  18. Halling KC, King W, Sokolova IA,et al.A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma.J Urol.2000;164:1768-1775.

  19. Amling CL,Diagnosis and management of superficial bladder cancer.Curr Prob Cancer25(4):.
The UroVysion Bladder Cancer Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.